Whistleblower David Howell Says DEA Let Fentanyl Flow Freely Through New Mexico

ALBUQUERQUE, N.M. — DEA agents allegedly watched fentanyl shipments move through New Mexico for nearly two years without seizing large quantities of pills, according to records and accounts from current and former agency personnel. Internal documents reviewed by reporters indicate hundreds of thousands of pills reached communities while federal investigators pursued broader trafficking targets.

Internal records reviewed by reporters describe agents tracking fentanyl shipments, documenting transactions and gathering intelligence while pills continued moving through Albuquerque-area distribution channels. According to the Associated Press, some current and former DEA personnel contend the agency allowed large quantities of the synthetic opioid to circulate in hopes of building broader criminal prosecutions against trafficking organizations.

David Howell, a veteran DEA agent who later became a whistleblower, argued the strategy exposed communities to unnecessary danger. Records reviewed by reporters showed investigators documenting specific deliveries, including one transaction involving roughly 74,000 pills that agents observed but did not seize.

Fentanyl remains the deadliest drug driving America's overdose crisis, with even small amounts capable of causing fatal overdoses. Concerns raised by current and former agents center on whether allowing shipments to proceed increased the likelihood that pills reached users while federal authorities pursued higher-level targets.

Former U.S. Attorney Alexander Uballez defended the broader approach, arguing investigators often face difficult choices when attempting to dismantle sophisticated trafficking operations. Supporters of long-term investigations maintain that prematurely interrupting shipments can jeopardize opportunities to identify suppliers, financiers and leaders directing distribution networks.

Documents examined by reporters indicate agents sometimes possessed detailed intelligence about quantities being transported and destinations tied to ongoing investigations. Critics inside and outside law enforcement have compared the allegations to previous federal controversies in which authorities were accused of permitting dangerous contraband to circulate while pursuing larger criminal cases.

Urgency for answers intensified after disclosures that as many as 1.8 million pills may have moved through investigations without seizure during the period examined by reporters. Questions about oversight, public safety safeguards and Justice Department guidelines now sit at the center of growing scrutiny surrounding the agency's tactics.

DEA officials have not publicly provided a detailed response addressing each allegation described in the reporting. Additional examination of agency practices could determine whether policy changes, disciplinary measures or further reviews emerge from one of the most closely watched fentanyl enforcement controversies in recent memory.